Editor’s Note: Have news to share? Send press releases, announcements, and news to [email protected].
IASLC recently named four highly regarded thoracic oncologists Narjust Florez, MD; Linda Martin, MD; Fabio Ynoe de Moraes, MD, Ph.D., MBA; and Sandip Patel, MD; as co-chairs of the association’s 2024 World Conference on Lung Cancer.
Co-chairs work with the IASLC to plan the annual meeting, select program track members and meeting content, and serve as ambassadors for international oncologists who attend the meeting.
Dr. Narjust Florez is the associate director of the Cancer Care Equity Program, a thoracic medical oncologist at the Dana-Farber Cancer Institute/Harvard Cancer Center, and an assistant professor of Medicine at Harvard Medical School. In 2022, Dr. Florez also became the first Latina to hold an associate editor position in oncology as the new associate editor for Diversity, Equity, and Inclusion at JAMA Oncology. She is the co-founder of the #LatinasInMedicine online community and the Florez Laboratory. Additionally, Dr. Florez is co-host of Lung Cancer Considered, the official IASLC podcast. She is also a member of the LATAM Working Group and is active with the IASLC’s Women in Thoracic Oncology Group.
Dr. Linda Martin is chief of Thoracic Surgery at the University of Virginia, where she holds the rank of tenured associate professor of surgery. She is vice-chair of the Respiratory Committee for Alliance and serves as an investigator in several clinical trials for multidisciplinary care of thoracic cancers. She is the Society of Thoracic Surgeons representative to the American College of Surgeons Commission on Cancer and is involved in multiple leadership roles to develop and implement cancer surgery standards. She is internationally recognized for her work on enhanced recovery in thoracic surgery, reducing opioid use, and speeding recovery of patients after lung cancer resection. Dr. Martin has served as invited faculty for the North America Conference on Lung Cancer and has been an IASLC member since 2017.
Dr. Fabio Ynoe de Moraes is an associate professor and principal investigator at Queen’s University, Kingston, Ontario, Canada, and a radiation oncologist focusing on exploring the intersection between health policy, innovation, and thoracic oncology, as well as a principal investigator in health services research and AI. Dr. Moraes is an active member of the IASLC, a past WCLC faculty member, and two-time IASLC Academy Award Winner.
Dr. Sandip Patel is a professor at the University of California San Diego and a medical oncologist focusing on early-phase clinical trials of immunotherapy and thoracic oncology. He is an active member of IASLC and serves on the Communications and Career Development & Fellowship Committees and was invited faculty at the 2020 Targeted Therapies of Lung Cancer meeting. Dr. Patel is the leader for the Experimental Therapeutics (Phase 1) Program and deputy director for the Center for Precision Immunotherapy at UCSD. Additionally, he is the director of the Clinical Trials Office at UCSD Moores Cancer Center, co-leader of the NRG Developmental Therapeutics Committee, and co-leader of the University of California Lung Cancer Consortium.
TTLC Abstract Submissions Close Soon
The IASLC Targeted Therapies of Lung Cancer (TTLC) meeting gathers experts to explore ongoing clinical trials of the newest therapies in lung cancer and to make sense of the data on relevant targets for novel therapies. TTLC 2023 will take place February 22-25 in Santa Monica, California.
Fellows, residents, and junior faculty within two years of appointment are eligible to submit abstracts to showcase their research and share in discussions with experts in the field—shaping the future of treatments in lung cancer and thoracic malignancies.
However, the abstract submission deadline is December 2, 2022, at 23:59 US Pacific Time. Incomplete or late abstracts will not be considered for inclusion in the program.
Submission categories include:
- Antibody Drug Conjugates
- Early-Stage Cancer, Immunotherapy
- Small Cell Lung Cancer
- Stage III Cancer
- Targeted Therapies
For more information and to submit abstracts, visit ttlc2023.iaslc.org/call-for-abstracts.
